We encourage patients to first discuss any questions or concerns regarding their existing treatments with their healthcare providers, as they are best informed about the specific healthcare needs of their patients and the potential risks associated with discontinuing or modifying treatment.

In the United States, patients with questions can contact Incyte’s U.S. Medical Information line at 1-855-4MED-INFO (1-855-463-3463) or send an email to medinfo@Incyte.com.

Outside the United States patients can call +800-0002-7423 or send an email to globalmedinfo@incyte.com or eumedinfo@incyte.com.

Eligible patients in the United States who are currently prescribed Jakafi® (ruxolitinib) or Pemazyre® (pemigatinib) can contact IncyteCARES (Connecting to Access, Reimbursement, Education and Support), a comprehensive program offering patient support, including financial assistance and ongoing education and resources for eligible patients.

More information about IncyteCARES is available by visiting www.incytecares.com or calling 1-855-4-Jakafi (855-452-5234).

Eligible patients in the United States who are currently prescribed Monjuvi® (tafasitamab-cxix) can contact My Mission Support, a robust patient support program offering financial assistance, ongoing education and other resources. For more information, please visit My Mission Support

Yes, ruxolitinib has been studied in patients with COVID-19.

DEVENT

• In March 2021, we announced results from the Phase 3 DEVENT study evaluating the efficacy and safety of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs, with disease severity requiring mechanical ventilation. Improvement in mortality for each dose compared to placebo (primary endpoint), while trending toward positive, was not statistically significant for the overall study population. However, results showed significant improvement in mortality in U.S. study participants at both doses, and in the overall population when data from both treatment arms was pooled. For more information, please see our press release.

RUXCOVID

• In December 2020, we announced results from the RUXCOVID (NCT04362137) trial, testing ruxolitinib in patients hospitalized with severe COVID-19 but whose disease did not yet require intubation. Initial data showed that treatment with ruxolitinib plus standard-of-care (SoC) did not reduce complications in these patients with COVID-19 associated cytokine storm. For more information, please see our press release.

Questions or inquiries regarding the DEVENT study or RUXCOVID study should be made to:

U.S. Medical Information

1-888-4MED-INFO (1-855-463-3463)

medinfo@incyte.com

At present, we have ample commercial and clinical supply of our medicines to meet the needs of patients receiving our approved medicines and those participating in our global clinical trials. The global COVID-19 outbreak has not had any impact on Incyte’s supply chain to-date, and we are working diligently to increase our manufacturing efforts in response to the COVID-19 pandemic.

Incyte is working closely with distribution partners to monitor supply of Jakafi and ensure safeguards are in place and will work rapidly to make sure that patients continue to have access to Jakafi that has been prescribed to them.

Additionally, we have taken precautions by ensuring that our current inventory of approved and investigational medicines is stored in different locations across the United States and Europe should one specific region or warehouse face a disruption.

We take the health and safety of our employees, their families and our local communities very seriously, and are closely monitoring the evolving COVID-19 pandemic. As such, we have put several measures in place to prepare for and protect against the transmission of COVID-19 in our facilities around the world and ensure we have the tools we need to support our work to serve patients. This includes:

• Enabling those who are able to work remotely to do so.
• Implementing additional cleanings throughout our campuses to help protect those who continue to work on site.
• Restricting visitor access.
• Restricting all global and domestic company air travel to trips that support essential business continuity.
• Working closely with appropriate health authorities and fully complying with all Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and applicable local government regulations and protocols.